Benjamin P. Saylor

The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.

J. Brantley Thrasher, MD, executive director of the American Board of Urology, spoke with Urology Times about what the ABU is doing to reduce the burden on urologists and their practice.

Henry Rosevear, MD, talks about how he and his practice are coping with the COVID-19 pandemic.

Jeb Bush touched on a range of issues in health care and politics and shared a few personal anecdotes about his famous family with LUGPA members at the association’s annual meeting in Chicago.

"I have worked in some fantastic urology departments where I've been supported by an amazing group of faculty and colleagues," says Leslie M. Rickey, MD, MPH.

Retrospective cohort study identifies wide variation in treatment rates, spending.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

In separate actions, the FDA allowed the marketing of a urinary prosthesis for women and approved a supplemental new drug application for a lymphatic mapping agent.

Ultrasound should be the initial diagnostic imaging test utilized for diagnosing kidney stones in order to reduce the higher radiation exposure associated with computed tomography, say the authors of a recent study.

Results of a study that included approximately 50,000 patients point to an association between kidney stones and incident cardiovascular disease and stroke.

Other products featured include a testosterone gel, exercise program to strengthen male pelvic muscles, and a book about prostate cancer diagnosis and management.

Transrectal ultrasound-guided prostate biopsy is associated with a rising rate of hospitalization for urinary tract infection, new study results indicate.

Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.

Increasing daily temperature appears to be associated with an increased risk of kidney stones, results of a recently published multicenter study suggest.

Landon Trost, MD, presents the take home messages on sexual function/dysfunction from the AUA annual meeting in Orlando, FL, including studies of clostridium collagenase histolyticum (CCH [XIAFLEX]).

Adonis K. Hijaz, MD, presents the take home messages on female urology/incontinence/urodynamics from the AUA annual meeting in Orlando, FL, including studies on mesh outcomes and the overactive bladder treatment mirabegron (Myrbetriq).

Richard K. Lee, MD, MBA, presents the take home messages on BPH/LUTS from the AUA annual meeting in Orlando, FL.

The majority of urologists and radiation oncologists feel active surveillance is an effective and underused modality for managing low-risk prostate cancer; however, few of these specialists would recommend this strategy to patients, according to recent survey results.

New products and services from TERUMO Medical Corp., TOLMAR Pharmaceuticals, Spry Publishing, and Beckman Coulter Diagnostics.

Drugs in the pipeline from Astellas Pharma, Medivation, TesoRx, Strategic Science and Technologies, Cubist Pharmaceuticals, and SCA.

When compared with shock wave lithotripsy, ureteroscopy is associated with fewer repeat treatments, according to a recent study from Duke University.

The FDA recently issued two proposed orders that, if finalized, would reclassify surgical mesh for transvaginal pelvic organ prolapse from a moderate-risk device (class II) to a high-risk device (class III) and require manufacturers to submit a premarket approval application for the agency to evaluate safety and effectiveness.

Despite their overall low risk, procedures to treat kidney stones lead to complications that require hospitalization or emergency care for one in seven patients, according to a recent study.

New products and services from Lumenis, ITelagen, Mission Pharmacal, PatientPoint, and HealthTronics IT Solutions.

Drugs and devices in the pipeline from MEI Pharma, Bayer HealthCare, Merck, Pfizer, and Minomic International.

Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.

New products and services from Accuray, Cook Medical, OPKO Health, Intuitive Surgical, Skipta, Mauna Kea Technologies, and the National Comprehensive Cancer Network.

The American Society of Cataract and Refractive Surgery and the American Academy of Ophthalmology have jointly issued an educational update about cataract surgery complications associated with systemic alpha-blockers based on the recent publication of two studies.

This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.